Appendix

BUFFERS, REAGENTS, SOLUTIONS

Sl No.	Buffer	Concentration
I.	Phosphate buffer saline (pH 7.4)	
	NaCl	8 gm/L
	KCl	0.2 gm/L
	Na_2HPO_4	1.42 gm/L
	KH2PO4	0.24 gm/L
II.	Sodium phosphate buffer 1M (pH 8.0)	
	1 M Solution of Na ₂ HPO ₄	53 ml/L
	1 M Solution of Na ₂ PO4	947 ml/L
III.	Sodium phosphate buffer 1M (pH 6.5)	
	1 M Solution of Na ₂ HPO ₄	685 ml/L
	1 M Solution of Na ₂ PO4	315 ml/L
IV.	Sodium phosphate buffer 1M (pH 7.0)	
	1 M Solution of Na ₂ HPO ₄	390 ml/L
	1 M Solution of Na ₂ PO4	610 ml/L
V.	Potassium phosphate buffer 1M (pH 7.5)	
	K_2HPO_4	69.67 gm/L
	KH_2PO_5	27.22 gm/L
VI.	Tris KCL buffer	
	KCL	74.55 gm/L
	Tris	121.14 gm/L
VII.	Normal Saline	
	NaCl	0.9 mg/L
VIII.	Lysis buffer	
	Tris-Cl (pH 8.0)	50mM
	NaCl	150mM
	Nonidet P-40	1X
	Sodium deoxycholate	0.50%
	SDS	0.10%
	Sodium orthovanadate	1mM
	NaF	1mM
	Protease inhibitor	1X

IX.	Loading buffer (2X) Tris-Cl (pH 6.8)	100 mM
	SDS	4%
	Bromophenol blue	0.20%
	Glycerol	20%
	Dithiothreitol	200 mM
X.	Running buffers (1x) (pH 8.3)	
	Tris base	3 gm/L
	Glycine	14.4 gm/L
	SDS	1 gm/L
XI.	Transfer buffer (1X)	
	Tris-Cl	25 mM
	Glycine	190 mM
	Methanol	20%
XII.	Wash buffer (1X)	
	Tris-Cl (Ph 7.5)	20 Mm
	NaCl	150 Mm
	Tween 20	0.10%
XIII.	Blocking buffer	
	Wash buffer	1X
	Non-fat milk powder	5%
XIV.	Stripping buffer	
	Glycine	15 gm/L
	SDS	1 gm/L
	Tween 20	1%
	β– mercaptoethanol	0.80%
XV.	Griess reagent	
	N-1-napthylethylenediamine dihydrochloride in water	50%
	Sulfanilamide in 5% phosphoric acid	50%





भारत सरकार / GOVERNMENT OF INDIA

पर्यावरण एवं वन मंत्रालय / MINISTRY OF ENVIRONMENT AND FORESTS संयुक्त निदेशक कार्यालय / OFFICE OF THE JOINT DIRECTOR भारतीय वनस्पति सर्वेक्षण / BOTANICAL SURVEY OF INDIA पूर्वी क्षेत्रीय केन्द्र / EASTERN REGIONAL CENTRE

शिलाग-793 003 / SHILLONG-793003

भारतीय वनस्यति सर्ववाण BOTANICAL SURVEY FINDIA

दूरभाष /Telephone: 0364- 2223971, 2223618

ई-मेल / e-mail-bsibsishll@yahoo.co.in

Telefax: 0364 -2224119

No.BSI/ERC/Tech./Plant Iden./2015/366,

Date: 03-08-2015

To

Anowar Hussain

Research Scholar

Department of Molecular Biology and Biotechnology

Tezpur University,

Napaam, Tezpur -786028, Assam

Subject: Identification and authentication of plant species.

Dear Hussain,

With reference to your letter No. Nil dated 30-07-2015 regarding the subject cited above, I am to inform you that your plant specimens have been identified and confirmed as below:

- 1. Phlogacanthus thyrsiflorus Nees (Family-Acanthaceae) (TU/MBBT/AMR/PS/02),
- 2. Nyctanthes arbor-tristis L. (Family-Oleaceae) (TU/MBBT/AMR/PS/03)
- 3. Alstonia scholaris (L.) R.Br.(Family Apocynaceae) (TU/MBBT/AMR/PS/04)
- 4. Basella alba L. (Family Basellaceae) (TU/MBBT/AMR/PS/05)

Thanking you.

Yours Sincerely

(डॉ ए. ए. माओ) /Dr. A.A. Mao

वैज्ञानिक ङ / Scientist-'E' & Head of Office



DEPARTMENT OF BOTANY GAUHATI UNIVERSITY

Gopinath Bardoloi Nagar, Guwahati - 781 014

2:0361 - 2570530


Ref. No	Date : 1.6/5


This is to costify that the plants have been identified and authenticated by me.

Professor

- 1) Allium hookerii
- (1) A. wallichic
- (m) Adhatoda vesica
- (10) Phlogacanthus sp.
 - (2) Basella rubra
 - (VI) Engajum Joekala
 - (VII) Alstonia scholaris
 - (VIII) Dyctanthe asborbish's

Professor
Department of Botany
Gauhati University
Guwahati-781014









TEZPUR UNIVERSITY

Office of the Dean, Research & Development Napaam::Tezpur – 784 028::Assam::India

No. DoRD/TUEC/10-14/4361

Date: 28.03.2614

To
Dr. A. Ramteke
Department of MBBT
Tezpur University

Sub: Research proposal submitted to TUEC.

Dear Dr. Ramteke,

This is with reference to the research proposal entitled "Use of isolated lymphocytes as a test model" which was submitted to the Tezpur University Ethical Committee for ethical clearance. The proposal was reviewed in the Tezpur University Ethical Committee (TUEC) meeting held on 30/09/2013. This is to inform you that the proposal has been accorded ethical approval.

Thanking you,

Yours sincerely,

Charn lata Mahauta (C.L. Mahanta) 28/3/1

Chairperson, TUEC

Copy to:

1. Professor S. Baruah, Dept. of MBBT, Member Secretary, TUEC.

Charn later Mahanler (C.L. Mahanta) 28/3/1014

Chairperson, TUEC

CERTIFICATE

This is certify that the project title. Chemo ph	enent,	re po	faction of	of hydroal	show
actmet of scheeled	· 'n	Sviss	altino	wu"	
has been approved by the IAEC.					

C.L. Mahauler

Name of Chairman/Member Secretary IAEC:

Name of CPCSEA nominee:

Signature with date

Chairman/Member Secretary of IAEC: 13/05

CPCSEA nominee:


(Kindly make sure that minutes of the meeting duly signed by all the participants are maintained by Office)

*Components identified in FENA Sample (Code: 93) [GC MS study]:

No.	RT	Name of the compound	Molecular Formulae	MW	Peak Area %
1.	6.43	9-Oxa-bicyclo[3.3.1]nonane-1,4-diol	C ₈ H ₁₄ O ₃	158	8.59
2.	6.94	2,5-Methano-2H-furo[3,2-b]pyran, hexahydro-	C ₈ H ₁₂ O ₂	140	13.56
3.	7.58	E-10-Pentadecenol	C ₁₅ H ₃₀ O	226	7.55
4.	8.52	Dodecanoic acid, 3-hydroxy-	C ₁₂ H ₂₄ O ₃	216	26.41
5.	9.87	Z-8-Methyl-9-tetradecenoic acid	C ₁₅ H ₂₈ O ₂	240	2.14
6.	10.53	á-D-Glucopyranose, 4-O-á-D-galactopyranosyl-	C ₁₂ H ₂₂ O ₁₁	342	4.81
7.	11.41	Cyclopentaneundecanoic acid, methyl ester	C ₁₇ H ₃₂ O ₂	268	0.78
8.	12.12	Hexadecanoic acid, ethyl ester	С18Н36О2	284	6.45
9.	12.39	n-Hexadecanoic acid	С16Н32О2	256	5.44
10.	13.28	9,12-Octadecadienoic acid (Z,Z)-	C ₁₈ H ₃₂ O ₂	280	0.47
11.	13.57	Phytol	C ₂₀ H ₄₀ O	296	5.93
12.	14.06	9,12-Octadecadienoic acid, ethyl ester	С20Н36О2	308	8.54
13.	14.43	Oleic Acid	C ₁₈ H ₃₄ O ₂	282	8.68
14.	17.03	E-11-Hexadecenoic acid, ethyl ester	C ₁₈ H ₃₄ O ₂	282	0.65

^{*}Parameters tested are not covered under the scope of NABL accreditation

GCMS Chromatogram



Annexure VI

Data Path : E:\GCMSD\2016\January\280116\

Data File : MSD.D

Acq On : 28 Jan 2016 12:44

Acq On . - Operator : Sample : LEPT (B2604)
Misc : 1 Sample M ALS Vial : 1 Sample Multiplier: 1

Integration Parameters: autoint1.e

Integrator: ChemStation

Method : E:\GC METHODA\HSRSSIM.M

: Pest-1 Title

Signal : TIC: MSD.D\data.ms

peak #	R.T. min	scan					corr. area		% of total
1	19.028		945	950	 M	38025	886421	0.24%	0.066%
	22.505		1275		M6			0.69%	0.188%
	24.121			1438		56069		0.96%	0.259%
	25.502		1560		M4	73247		0.84%	0.227%
	26.581			1677		106477		1.00%	0.270%
	31.721			2156			2652348	0.73%	0.197%
	34.795			2450		214111	5324459	1.46%	0.395%
	35.298		2491		М9	55857		0.50%	0.136%
	35.668		2526		M4	68406		0.52%	0.142%
10	36.466	2581	2602	2607	BV	533363	23336284	6.40%	1.731%
	37.442						151879312		11.269%
	39.502					156601	5724628		0.425%
	39.769			2921		2547477			6.527%
	39.904						364352456		
15	40.113	2944	2949	2964	VV	1703522	49903275	13.70%	3.703%
16	40.423	2964	2978	2988	PV	1674747	49380064	13.55%	3.664%
	41.434			3082		136491		1.16%	0.313%
	41.763			3110			4215412	1.16%	0.313%
	42.610			3192		239717		1.85%	0.501%
20	43.492	3264	3270	3286	PV 2	154039	5114480	1.40%	0.379%
	44.479	3357	3364	3396	VV	519372	28653525	7.86%	2.126%
22	45.545	3457	3465	3471	VV 6	142163	4963785	1.36%	0.368%
23	45.672			3492		160292	6164138	1.69%	0.457%
	46.582			3569		367311	11401663	3.13%	0.846%
25	46.779	3577	3582	3589	VV 2	252999	8506411	2.33%	0.631%
26	47.177	3611	3620	3640	VV	851269	26276519	7.21%	1.950%
27	48.333	3724	3730	3733	M2	217286	6843536	1.88%	0.508%
28	50.866	3955	3971	3994	VV	1371456	78547020	21.56%	5.828%
	51.342			4024		351237	12423054	3.41%	0.922%
30	53.196	4186	4192	4195	VV 3	400602	16013991	4.40%	1.188%
31	53.787	4240	4248	4263	VV 3	2641695	110287053	30.27%	8.183%
	54.006	4263	4269	4275	VV 4	362294	15509165	4.26%	1.151%
	54.361			4313				4.53%	1.225%
	54.582			4337		707712	36449758	10.00%	2.704%
35	54.805	4337	4345	4352	VV 5	616407	29548051	8.11%	2.192%
	55.155						100440912	27.57%	7.452%
	55.553			4427					0.609%
	55.979			4465				2.13%	0.575%
	56.552			4530				4.46%	1.206%
40	57.855	4618	4635	4648	VB 8	165628	9519854	2.61%	0.706%
41	59.736	4805	4814	4838	VV 8	162023	12171130	3.34%	0.903%
42	60.149	4838	4853	4863	PV 8	140666	7163072	1.97%	0.531%

Screening data

Annexure VII

Effects of different fractions of Nyctanthes arbor-tristis on the viability of human lung cancer H1299 cells




Figure. Effects of different fractions of *Nyctanthes arbor-tristis* on the viability of human lung cancer H1299 cells: H1299 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

i

Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human lung cancer H1299 cells




Figure. Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human lung cancer H1299 cells: H1299 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of Nyctanthes arbor-tristis on the viability of human lung cancer A549 cells




Figure. Effects of different fractions of *Nyctanthes arbor-tristis* on the viability of human lung cancer A549 cells: A549 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human lung cancer A549 cells




Figure. Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human lung cancer A549 cells: A549 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of Nyctanthes arbor-tristis on the viability of human prostate cancer PC3 cells




Figure. Effects of different fractions of *Nyctanthes arbor-tristis* on the viability of human prostate cancer PC3 cells: PC3 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human prostate cancer PC3 cells




Figure. Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human prostate cancer PC3 Cells: PC3 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of Nyctanthes arbor-tristis on the viability of human prostate cancer LNCap cells




Figure. Effects of different fractions of *Nyctanthes arbor-tristis* on the viability of human prostate cancer LNCap cells: LNCap cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human prostate cancer LNCap cells




Figure. Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human prostate cancer LNCap cells: LNCap cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of Nyctanthes arbor-tristis on the viability of human colon cancer SW480 cells




Figure. Effects of different fractions of *Nyctanthes arbor-tristis* on the viability of human colon cancer SW480 cells: SW480 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human colon cancer SW480 cells




Figure. Effects of different fractions of *Phlogacanthus thyrsiflorus* on the viability of human colon cancer SW480 cells: SW480 cells treated with various concentration of fractions in DMSO for 24-48 hrs. At the end of each treatment duration, viability was measured by MTT assay as mentioned in 'Material and Methods', and % cell viability are shown. The values are represented as mean \pm SEM of three samples for each treatment. c, P < 0.05; b, P < 0.01; a, P < 0.001.

Data File F3NAF.d Sample Name F3NAF Sample Type Sample Position P1-A1 User Name Acquired Time Instrument Name

Instrument 1 30mins_+ESI_10032014.m Success Acq Method 1/6/2016 4:14:38 PM IRM Calibration Status DA Method default.m

Comment

Sample Group Acquisition SW Version 6200 series TOF/6500 series Q-TOF B.05.01 (B5125.1)

Compound Label	RT 0.505	Mass	Name isoamv nitrite	Formula C5 H11 N O2	MFG Formula C5 H11 N O2	DB Formula C5 H11 N O2	DB Diff(ppm)	Hits (DB)
Cpd 1: isoamyl nitrite Cpd 2: 0.509	0.505	101.12	isoamy i nitrite	C5 H11 N O2	C5 H11 N O2	CS H11 N O2	5.67	, J
Cpd 3: Methyl N-(a- methylbutyryl)glycine	0.514		Methyl N-(a- methylbutyryl)glycine	OS H15 N O3	OS H15 N O3	OS H15 N O3	2.73	1
Cpd 4: Nefopam	0.523	253 1519	Nefopam	C17 H19 N O	C17 H19 N O	C17 H19 N O	-20.54	60
Cpd 5: 2-Aminomuconate 6-	0.546		2-Aminomuconate 6-	06 H7 N O3	C6 H7 N O3	05 H7 N O3	2.78	60
semialdehyde			semial de hy de					
Cpd 6: 2-Aminomuconate 6- semialdehyde	0.674	141.0423	2-Aminomuconate 6- semialdehyde	C6 H7 N O3	O6 H7 N O3	O5 H7 N O3	2.32	
Cpd 7: 1-Methyl-5- imidazoleacetic acid	0.675	140.0582	1-Methyl-5-imidazoleacetic acid	C6 H8 N2 O2	C6 H8 N2 O2	C6 H8 N2 O2	3.03	
Cpd 8: 1-(3-Carboxypropyl)- 3,7-dimethylxanthine	0.747	266.0996	1-(3-Carboxypropyl)-3,7- dimethylxanthine	C11 H14 N4 O4	C11 H14 N4 O4	C11 H14 N4 O4	7.3	
Cpd 9: 2-octynoic acid	0.975	140 0832	2-octynoic acid	C8 H12 O2	C8 H12 O2	C8 H12 O2	3.91	92
Cpd 10: Shikimic acid	3,081		Shikimic acid	C7 H10 O5	C7 H10 O5	C7 H10 O5	3.2	-
Cpd 11: Ethyl Oxalacetate	3.874	57 V V V V V V V V V V V V V V V V V V V	Ethyl Oxalacetate	OS H12 O5	C8 H12 O5	08 H12 O5	2.71	
Cpd 12: Asn Ala Cys	3,906		Asn Ala Cys	C10 H18 N4 O5 S	C10 H18 N4 O5 S	C10 H18 N4 O5 S	17.36	3
Cpd 13: 2-Furanpropionic acid, tetrahydro-a-(1- naphthylmethyl)-	3.984		2-Furanpropionic acid, tetrahydro-a-(1- naphthylmethyl)-	C18 H20 O3	C18 H20 O3	C18 H20 O3	-16.34	2
pd 14: 4-Hydroxylevamisole Glucuronide	4.539	396.102	4-Hydroxylevamisole Glucuronide	C17 H20 N2 O7 S	C17 H20 N2 O7 S	C17 H20 N2 O7 S	-7.18	S.
Cpd 15: 6-propionyl n- caproic acid	4.707	172.1094	6-propionyl n-caproic acid	C9 H16 O3	C9 H16 O3	C9 H16 O3	3.06	50
Cpd 16: Methyl o- methoxyhippuric acid	4.996	223.0838	Methyl o-methoxyhippuric acid	C11 H13 N O4	C11 H13 N O4	C11 H13 N O4	2.79	3
Cpd 17: Quinol glucuronide	5.022	286.0679	Quinol glucuronide	C12 H14 O8	C12 H14 O8	C12 H14 O8	4.63	13
Cpd 18: 9-hydroxy-2E- decenoic acid	5.032		9-hydroxy-2E-decenoic acid	C10 H18 O3	C10 H18 O3	C10 H18 O3	3.14	
Cpd 19: Methyl o- methoxyhippuric acid	5.083	223.0839	Methyl o-methoxyhippuric acid	C11 H13 N O4	C11 H13 N O4	C11 H13 N O4	2.72	-55
Cpd 20: Phe His	5.376	302.1356	Phe His	C15 H18 N4 O3	C15 H18 N4 O3	C15 H18 N4 O3	7.43	47
Cpd 21: Ibuprofen	5.414		Ibuprofen	C13 H18 O2	C13 H18 O2	C13 H18 O2	2.16	100
Cpd 22: Methyl jasmonate	5.422		Methyl jasmonate	C13 H20 O3	C13 H20 O3	C13 H20 O3	2.77	100
Cpd 23: Benzenemethanol, 2 (2-aminopropoxy)-3-methyl-	5.799	196.1094	Benzenemethanol, 2-(2- aminopropoxy)-3-methyl-	C11 H16 O3	C11 H16 O3	C11 H16 O3	2.61	
Cpd 24: Isovaleric acid	5.878	102.0676	Isovaleric acid	C5 H10 O2	C5 H10 O2	C5 H10 O2	4.21	66
Cpd 25: 2E,7E-decadienoic acid	5.878	168.1145	2E,7E-decadienoic acid	C10 H16 O2	C10 H16 O2	C10 H16 O2	3.13	
Cpd 26: 4-octenal	5.878	126.104	4-octenal	C8 H14 O	C8 H14 O	C8 H14 O	3.9	.0
Cpd 27: 2-nonenal	5.878	140.1196	2-nonenal	C9 H16 O	C9 H16 O	C9 H16 O	3.89	19.
Cpd 28: beta-nonylenic acid	5.879	156.1144	beta-nonylenic acid	C9 H16 O2	C9 H16 O2	C9 H16 O2	4.01	
Cpd 29: 9-hydroxy-2E- decenoic acid	5.893	186.125	9-hydroxy-2E-decenoic acid	C10 H18 O3	C10 H18 O3	C10 H18 O3	3.39	
Cpd 30: (22R)-1alpha,22,25- trihydroxy-26,27-dimethyl- 23,24-tetradehydro-24a- homo-20-epivitamin D3 / (22R)-1a	5.897	470.3445	(22R)-1alpha,22,25- trihydroxy-26,27-dimethyl- 23,24-tetradehydro-24a- homo-20-epivitamin D3 / (22R)-1a	C30 H46 O4	C30 H46 O4	C30 H46 O4	-10.49	8
Cpd 31: Hydroxyibuprofen	6.016	200000000000000000000000000000000000000	Hydroxyibuprofen	C13 H18 O3	C13 H18 O3	C13 H18 O3	2.03	8
Cpd 32: Hydroxyibuprofen	6.019		Hydroxyibuprofen	C13 H18 O3	C13 H18 O3	C13 H18 O3	2.8	55
Opd 33: Benzenemethanol, 2- (2-aminopropoxy)-3-methyl-	6.072	196.1095	Benzenemethanol, 2-(2- aminopropoxy)-3-methyl-	C11 H16 O3	C11 H16 O3	C11 H16 O3	2.09	00
Cpd 34: 6.109	6.109	565.418						3
Cpd 35: 4-(2- hydroxypropoxy)-3,5-	6.203	196.1094	4-(2-hydroxypropoxy)-3,5- dimethyl-Phenol	C11 H16 O3	C11 H16 O3	C11 H16 O3	2.56	6
Cpd 36: LOGANIC ACID	6.386		LOGANIC ACID	C16 H24 O10	C16 H24 O10	C16 H24 O10	4.63	
Cpd 37: Methyl jasmonate	6.627		Methy I jasmonate	C13 H20 O3	C13 H20 O3	C13 H20 O3	2.58	60
Cpd 38: Citronellic acid	6.96		Citronellic acid	C10 H18 O2	C10 H18 O2	C10 H18 O2	3.19	o o
Cpd 39: Mitoxantrone Cpd 40: Acetylsalicylic acid	7.036		Mitoxantrone Acetylsalicylic acid (aspirin)	C22 H28 N4 O6 C9 H8 O4	C22 H28 N4 O6 C9 H8 O4	C22 H28 N4 O6 C9 H8 O4	7.59 2.71	
(aspirin)	7076	200 1710	Cla Cla Ass	C14 H34 H5 O7	C14 H24 HC 02	C14 H24 H5 O7	2.04	· K
Cpd 41: Gln Gln Asn	7.076 7.077		Gln Gln Asn	C14 H24 N6 O7 C14 H18 O4	C14 H24 N6 O7 C14 H18 O4	C14 H24 N6 O7 C14 H18 O4	-3.04 2.33	100
Cpd 42: Ubiquinone Cpd 43: Phe Tyr Gln	7.077		Ubiquinone Phe Tyr Gln	C23 H28 N4 O6	C14 H18 O4 C23 H28 N4 O6	C14 H18 O4 C23 H28 N4 O6	2.33	-
Cpd 44: Deutzioside	7.141		Deutzioside	C15 H22 O9	C15 H22 O9	C15 H22 O9	3.88	60
Cpd 45: PGD2	7.183	352.2235		C20 H32 O5	C20 H32 O5	C20 H32 O5	4.23	00
Cpd 46: Ubiquinone	7.285		Ubiquinone	C14 H18 O4	C14 H18 O4	C14 H18 O4	2.56	10
Cpd 47: Gln Gln Asn	7.287		Gln Gln Asn	C14 H24 N6 O7	C14 H24 N6 O7	C14 H24 N6 O7	-3.61	10.

Cpd 49: Nerolidyl diphosphate	7.348	382.1247	Nerolidyl diphosphate	C15 H28 O7 P2	C15 H28 O7 P2	C15 H28 O7 P2	16.54	1
Cpd 50: Phenylmethyl methyl ketone	7.414	134.0725	Phenylmethyl methyl ketone	C9 H10 O	C9 H10 O	C9 H10 O	4.93	1
Cpd 51: Ginkgolide B	7.509		Ginkgolide B	C20 H24 O10	C20 H24 O10	C20 H24 O10	3.41	- 3
Cpd 52: Penicilloic acid V Cpd 53: 2-Keto-3-	7.566 7.567		Penicilloic acid V 2-Keto-3-deoxyoctonate	C16 H20 N2 O6 S O8 H14 O8	C16 H20 N2 O6 S C8 H14 O8	C16 H20 N2 O6 S O8 H14 O8	-8.42 2.24	1
deoxyoctonate (KDO)	,,50,	1000090000	(KDO)	CO 1121 CC	G 1121 GG	G 1127 GG	57.	
Cpd 54: m-Cresol	7.567	108.0571		C7 H8 O	C7 H8 O	C7 H8 O	4.17	- 1
Cod 55: His Ser Val	7.568 7.812		His Ser Val Hydroxyibuprofen	C14 H23 N5 O5 C13 H18 O3	C14 H23 N5 O5 C13 H18 O3	C14 H23 N5 O5 C13 H18 O3	1.4 2.51	1
Cpd 56: Hydroxyibuprofen Cpd 57: 3-Phenoxypropionic	7.812		3-Phenoxy propionic acid	C9 H10 O3	C9 H10 O3	C9 H10 O3	1.67	1
acid	7.856	1110-1000-00	Tyr Gln Tyr	C23 H28 N4 O7	C23 H28 N4 O7	C23 H28 N4 O7	00000	1
Cpd 58: Tyr Gln Tyr Cpd 59: PHENETHICILLIN	7.836	13-501-03311-050	PHENETHICILLIN	C17 H20 N2 O5 S	C17 H20 N2 O5 S	C17 H20 N2 O5 S	6.46 -14.98	
Cpd 60: 7.951	7.951	750.2109		200000000000000000000000000000000000000			2,300	
Cpd 61: Nerolidyl diphosphate	7.953	382.1249	Nerolidyl diphosphate	C15 H28 O7 P2	C15 H28 O7 P2	C15 H28 O7 P2	15.97	1
Cpd 62: Methyl jasmonate	8.027	224.1407	Methy I jasmonate	C13 H20 O3	C13 H20 O3	C13 H20 O3	2.5	1
Cpd 63: 4,10-undecadiynal	8.035		4,10-undecadiynal	C11 H14 O	C11 H14 O	C11 H14 O	4.44	1
Cpd 64: 4-Ethylbenzoic acid	8.062	150.0676	4-Ethylbenzoic acid	C9 H10 O2	C9 H10 O2	C9 H10 O2	3.43	1
Cpd 65: 2-Hydroxy-3-(4-	8.067	240 0002	2-Hydroxy-3-(4-	C12 H16 O5	C12 H16 O5	C12 H16 O5	2.3	1
methoxye thylphenoxy)- propanoic acid	6.007	290,0332	methoxyethylphenoxy)- propanoic acid	C12 1110 O3	C12 11 15 C3	CI2 HID OS	2.3	1
Cpd 66: Asn Asn Asn	8.067	360.1412	Asn Asn Asn	C12 H20 N6 O7	C12 H20 N6 O7	C12 H20 N6 O7	-5.09	1
Cpd 67: Val Thr His	8.067		5.000 0000	C15 H25 N5 O5	C15 H25 N5 O5	C15 H25 N5 O5	1.26	1
Cpd 68: Acetylsalicylic acid	8.074	AL	Acetylsalicylic acid (aspirin)	C9 H8 O4	C9 H8 O4	C9 H8 O4	2.99	1
(aspirin)			# 10 WOOD 187					_
Cpd 69: Met Asn Gly	8.074	0	Met Asn Gly Met Trp Glu	C11 H20 N4 O5 S	C11 H20 N4 O5 S	C11 H20 N4 O5 S	10.4	1
Cpd 70: Met Trp Glu Cpd 71: 8.096	8.076 8.096	464.1667 236.1406	net irp Gid	C21 H28 N4 O6 S	C21 H28 N4 O6 S	C21 H28 N4 O6 S	13.38	- 10
Cpd 72: Mitoxantrone	8.152	0 0	Mitoxantrone	C22 H28 N4 O6	C22 H28 N4 O6	C22 H28 N4 O6	7	1
Cpd 73: Farnesyl pyrophosphate	8.176	382.1252	Famesyl pyrophosphate	C15 H28 O7 P2	C15 H28 O7 P2	C15 H28 O7 P2	15.17	1
Cpd 74: 2-Hydroxy-3-(4- methoxyethylphenoxy)- propanoic acid	8.354	240.0993	2-Hydroxy-3-(4- methoxyethylphenoxy)- propanoic acid	C12 H16 O5	C12 H16 O5	C12 H16 O5	2.14	1
Cpd 75: 2-Keto-3-	8.354	238.0683	2-Keto-3-deoxyoctonate	C8 H14 O8	C8 H14 O8	C8 H14 O8	2.45	- 8
deoxyoctonate (KDO) Cpd 76: 4-Ethylbenzoic acid	8.354	150.0675	(KDO) 4-Ethylbenzoic acid	C9 H10 O2	C9 H10 O2	C9 H10 O2	3.57	1
			21		2	3	(2) (3)	
Cpd 77: Asn Asn Asn	8.355	4000 0410 0000	Asn Asn Asn	C12 H20 N6 O7	C12 H20 N6 O7	C12 H20 N6 O7	4.16	1
Cpd 78: Val Thr His pd 79: Phenylmethyl methyl	8.355 8.355		Val Thr His Phenylmethyl methyl ketone	C15 H25 N5 O5 C9 H10 O	C15 H25 N5 O5 C9 H10 O	C15 H25 N5 O5 C9 H10 O	0.76 5.03	-
ketone pd 80: Desmethylnaproxen-	8.409	700040001746.0	Desmethylnaproxen-6-0-	C19 H20 O9	C19 H20 O9	C19 H20 O9	3.25	1
6-0-glucuronide	900101000	100000000000000000000000000000000000000	glucuronide	With Subsection	STEPSOTOGACAERS II.	4.561507.001674.0406.0301	5677007	
Cpd 81: 1-Methyl-4-nitro-5- (S-Gluctathionyl) Imidazole	8.416	432.1047	1-Methyl-4-nitro-5-(S- Gluctathionyl) Imidazole	C14 H20 N6 O8 S	C14 H20 N6 O8 S	C14 H20 N6 O8 S	3.84	
Cpd 82: alpha-Ery throidine	8.429		alpha-Erythroidine	C16 H19 N O3	C16 H19 N O3	C16 H19 N O3	2.3	1
Cpd 83: Fluorinolone	8.45		Huocinolone	C2.1 H26 F2 O6	C21 H26 F2 O6	C21 H26 F2 O6	0.13	1
Cpd 84: Ginkgolide A Cpd 85: 8.500	8.5 8.5	406.1405 552.1823	Ginkgolide A	C20 H24 O9	C20 H24 O9	C20 H24 O9	3.67	1
Cpd 86: 8.590	8.59	584.1719						
Cpd 87: Fluorinolone	8.64		Fluocinolone	C21 H26 F2 O6	C21 H26 F2 O6	C21 H26 F2 O6	1.12	1
Cpd 88: Salicin	8.668	286.1067	777 TOWN 1777 17	C13 H18 O7	C13 H18 O7	C13 H18 O7	-5.08	y,
Cpd 89: Pheny Ipyruvic acid	8.67		Phenylpyruvic acid	C9 H8 O3	C9 H8 O3	C9 H8 O3	2.16	1
Cpd 90: Cys Trp Tyr Cpd 91: Lys Glu Lys	8.676 8.751		Cys Trp Tyr Lys Glu Lys	C23 H26 N4 O5 S C17 H33 N5 O6	C23 H26 N4 O5 S C17 H33 N5 O6	C23 H26 N4 O5 S C17 H33 N5 O6	17.99	1
Cpd 92: Fluorinolone	8.751		Ruocinolone	C21 H26 F2 O6	C21 H26 F2 O6	C21 H26 F2 O6	0.68	1
Cpd 93: a-N- Acetylneuraminyl-2,6-b-D- galactosyl-1,4-N-acetyl-b-D- glucosamine	8.838	674.2525	a-N-Acetylneuraminyl-2,6-b- D-galactosyl-1,4-N-acetyl-b-D- glucosamine	C25 H42 N2 O19	C2.5 H42 N2 O19	C25 H42 N2 O19	-21.18	7
Cpd 94: 8.872	8.872	554.2107					51.9	
Cpd 95: Ginkgolide A	8.994		Ginkgolide A	C20 H24 O9	C20 H24 O9	C20 H24 O9	7.32	1
Cpd 96: CLOVANEDIOL DIACETATE	9.017	10 No. 10	CLOVANEDIOL DIACETATE	C19 H30 O4	C19 H30 O4	C19 H30 O4	3.04	1
pd 97: Desmethylnaproxen- 6-O-glucuronide	9.188	200000000000000000000000000000000000000	Desmethylnaproxen-6-0- glucuronide	C19 H20 O9	C19 H20 O9	C19 H20 O9	1.84	ji
pd 98: Desmethylnaproxen- 6-O-glucuronide	9.191	392.1095	glucuronide	C19 H20 O9	C19 H20 O9	C19 H20 O9	3.02	- 8
Cpd 99: His Glu Gln	9.307 9.308	412.174 578.198	His Glu Gln	C16 H24 N6 O7	C16 H24 N6 O7	C16 H24 N6 O7	-8.26	1
Cpd 100: 9.308 Cpd 101: 9.309	9.308	5/8.198	9					
Cpd 102: N- idesethylquinagolide sulfate	9.396	V. 19/20/27 V.	N-Didesethylquinagolide sulfate	C16 H25 N3 O6 S2	C16 H25 N3 O6 S2	C16 H25 N3 O6 S2	-5.4	1
Cpd 103: Dihydrodeoxystreptomycin	9.401	567.2872	Dihydrodeoxystreptomycin	C21 H41 N7 O11	C21 H41 N7 O11	C21 H41 N7 O11	-1.33	- 0
Cpd 104: SWIETENINE	9.401	568.2705	SWIETENINE	C32 H40 O9	C32 H40 O9	C32 H40 O9	-5.71	- 8
Cpd 105: Fenoprofen glucuronide	9.479		Fenoprofen glucuronide	C2.1 H22 O9	C21 H22 O9	C21 H22 O9	2.35	9
Cpd 106: Phloridzin	9.481	436.1356	Phloridzin	C21 H24 O10	C21 H24 O 10	C21 H24 O 10	3.09	1
Cpd 107: 2E,7E-decadienoic	9.582	II. III.gggman acq	2E,7E-decadienoic acid	C10 H16 O2	C10 H16 O2	C10 H16 O2	3.7	1
						ı I		
acid Cpd 108: 16-hydroxy-5-	9.609	270 2107	16-hydroxy-5-hexadecenoic	C16 H30 O3	C16 H30 O3	C16 H30 O3	2.97	1

Cpd 109: 10Z,12E-	9.61	252 2082	10Z,12E-hexadecadienoic	C16 H28 O2	C16 H28 O2	C16 H28 O2	2.72	15
hexadecadienoic acid	5.01	232.2002	acid	C10 1125 G2	C10 1120 02	C10 1120 G2	2.72	13
Cpd 110: 9.650 Cpd 111: Neu5Gcalpha2-	9.65 9.685	180.1145	Neu5Gcalpha2-3Galbeta1-	C25 H42 N4 O20	C25 H42 N4 O20	C2.5 H42 N4 O20	24.77	
3Galbeta 1-4Glcbe ta-Sp	9,063	/10.2213	4Glcbeta-Sp	C231142 NH 020	C231H2 NA 020	G251H2 N4 O20	24.77	
Cpd 112: Torasemide	9.685		Torasemide	C16 H20 N4 O3 S	C16 H20 N4 O3 S	C16 H20 N4 O3 S	16.6	15
Cpd 113: 9.742 Cpd 114: 9.785	9.742 9.785	670.1875 568.1769	4					
Cpd 115: Hexadecanedioic	10.011		Hexadecanedioic acid	C16 H30 O4	C16 H30 O4	C16 H30 O4	2.91	6
acid Cpd 116: (24R)-25-fluoro-	10.058	440 2202	(24R)-25-fluoro-1alpha,24-	C28 H45 F O3	C28 H45 F O3	C28 H45 F O3	-6.7	- 1
rethylvitamin D3 / (24R)-25- fluoro-1alpha,24-dihydroxy- 24-met	10.058	446.3363	dihydroxy-24-methylvitamin D3 / (24R)-25-fluoro- 1alpha,24-dihydroxy-24-met	(26 H3 F03	(28 H3 F03	(26 H3 F03	-6.7	
Cpd 117: 4-Ketoretinoic acid glucuronide	10.148	490.2207	4-Ketoretinoic acid glucuronide	C26 H34 O9	C26 H34 O9	C26 H34 O9	-0.88	5
Cpd 118: Tyr Trp Tyr	10.151	17 17 17 17 17 17 17 17 17	Tyr Trp Tyr	C29 H30 N4 O6	C29 H30 N4 O6	C29 H30 N4 O6	6.1	6
Cpd 119: Phloridzin Cpd 120: Terazosin	10.18 10.271	U 01/09/05/05/05/05	Phloridzin Terazosin	C21 H24 O10 C19 H25 N5 O4	C21 H24 O10 C19 H25 N5 O4	C21 H24 O 10 C19 H25 N5 O4	4.02 1.17	15
Cpd 120: Terazosin Cpd 121: 2,3-Dinor-6,15-	10.271	1,000,000,000	2,3-Dinor-6,15-diketo-13,14-	C18 H26 O8	C19 H25 N3 O4	C19 H25 N5 O4 C18 H26 O8	-1.81	15
diketo-13,14-dihydro-20- carboxyl-PGF1a	2012.	370,203	dihydro-20-carboxyl-PGF1a	010 1120 00	010 1120 00	010 1120 00		
Cpd 122: Elephantopin	10.276		Elephantopin	C19 H20 O7	C19 H20 O7	C19 H20 O7	3.55	15
Cpd 123: b-D- Glucopyranosiduronic acid, 6- (3-hydroxybutyl)-2-	10.286	392.1463	b-D-Glucopyranosiduronic acid, 6-(3-hydroxybutyl)-2- naphthalenyl	C20 H24 O8	C20 H24 O8	C20 H24 O8	2.13	15
Cpd 124: (24R)-25-fluoro- lalpha,24-dihydroxy-24- methylvitamin D3 / (24R)-25- fluoro-1alpha,24-dihydroxy- 24-met	10.316	448.3383	(24R)-25-fluoro-1alpha,24- dihydroxy-24-methylvitamin D3 / (24R)-25-fluoro- 1alpha,24-dihydroxy-24-met	C28 H45 F03	C28 H45 F03	C28 H45 F03	-6.78	2
Cpd 125: Trandolaprilat glucuronide	10.371	578.2345	Trandolaprilat glucuronide	C28 H38 NZ O11	C28 H38 N2 O11	C28 H38 N2 O11	22.6	1
Cpd 126: 2,3-Dinor-6,15- diketo-13,14-dihydro-20- carboxyl-PGF1a	10.456	370.1634	2,3-Dinor-6,15-diketo-13,14- dihydro-20-carboxyl-PGF1a	C18 H26 O8	C18 H26 O8	C18 H26 O8	-1.67	15
Cpd 127: Terazosin	10.456	387 1001	Terazosin	C19 H25 N5 O4	C19 H25 N5 O4	C19 H25 N5 O4	1.45	15
Cpd 128: MYCOPHENOLIC	10.456		MYCOPHENOLIC ACID	C17 H20 O6	C17 H20 O6	C17 H20 O6	-3.44	15
ACID	(0	400000000		500001 (\$2500) \$2550			50%	
Cpd 129: b-D- Glucopyranosiduronic acid, 6- (3-hydroxybutyl)-2-	10.457	392.1461	b-D-Glucopyranosiduronic acid, 6-(3-hydroxybutyl)-2- naphthalenyl	C20 H24 O8	C20 H24 O8	C20 H24 O8	2.72	15
Cpd 130: 4-oxo- 9Z,11Z,13E,15E- octadeca tetraenoic acid	10.483	290.1871	4-oxo-9Z,11Z,13E,15E- octadecatetraenoic acid	C18 H26 O3	C18 H26 O3	C18 H26 O3	3.85	13
Cpd 131: ACECLIDINE	10.56	169.11	ACECLIDINE	C9 H15 N O2	C9 H15 N O2	C9 H15 N O2	1.74	10
Cpd 132: Pro Thr Trp	10.56		Pro Thr Trp	C20 H26 N4 O5	C20 H26 N4 O5	C20 H26 N4 O5	-5.59	15
Cpd 133: 7-[2- TRIFLUOROMETHYL-4-(2- HYDROXYPHENYL)-1,3- DIOXAN-cis-5-YL]-HEPT-52- FNOIC ACID	10.64	3/4.1349	7-[2-TRIFLUOROMETHYL-4- (2-HYDROXYPHENYL)-1,3- DIOXAN-as-5-YL]-HEPT-5Z- ENOIC ACID	C18 H21 F3 O5	C18 H21 F3 O5	C18 H21 F3 O5	-2.05	15
Cpd 134: gamma- Hydroxyphenylbutazone glucuronide	10.696	500.1689	gamma - Hydroxyphenylbutazone glucuronide	C25 H28 N2 O9	C25 H28 N2 O9	C25 H28 N2 O9	21,15	2
Cpd 135: 10.698	10.698	684.2029	30				67	
Cpd 136: QUERCETIN TETRAMETHYL (5,7,3',4') ETHER	10.76	358.1035	QUERCETIN TETRAMETHYL (5,7,3',4') ETHER	C19 H18 O7	C19 H18 O7	C19 H18 O7	5,01	12
Cpd 137: Ginkgolide A	10.763	408.1407	Ginkgolide A	C20 H24 O9	C20 H24 O9	C20 H24 O9	3.17	15
Cpd 138: 4-Methoxycinnamic acid	10.797		4-Methoxycinnamic acid	C10 H10 O3	C10 H10 O3	C10 H10 O3	1.81	9
Cpd 139: 10.797	10.797	670.2239			si .			
Cpd 140: 10.836 Cpd 141: XYLOCARPUS A	10.836 11.173	256.084	XYLOCARPUS A	C31 H38 O11	C31 H38 O11	C31 H38 O11	3.78	
Cpd 142: Ile Trp Asn	11.1/3		Ile Trp Asn	C21 H29 N5 O5	C21 H29 N5 O5	C21 H29 N5 O5	0.94	15
Cpd 143: Thr Cys Arg	11.25	378.1688	Thr Cys Arg	C13 H26 N6 O5 S	C13 H26 N6 O5 S	C13 H26 N6 O5 S	-0.74	15
Cpd 144: Gibberellin A8	11.253		Gibberellin A8	C19 H24 O7	C19 H24 O7	C19 H24 O7	-3.19	15
Cpd 145: TRIPTONIDE Cpd 146: Thr Trp Met	11.25 4 11.258	ACT BY ANY OWN	TRIPTONIDE Thr Trp Met	C20 H22 O6 C20 H28 N4 O5 S	C20 H22 O6 C20 H28 N4 O5 S	C20 H22 O6 C20 H28 N4 O5 S	3.64 15.72	15
Cpd 147: Folic acid	11.42	The second second second	Folic acid	C19 H19 N7 O6	C19 H19 N7 O6	C19 H19 N7 O6	-2.23	1
Cpd 148: Ile Trp Asn	11.449	431.2162	Ile Trp Asn	C21 H29 N5 O5	C21 H29 N5 O5	C21 H29 N5 O5	1.55	15
Cpd 149: Thr Cys Arg	11.449		Thr Cys Arg	C13 H26 N6 O5 S	C13 H26 N6 O5 S	C13 H26 N6 O5 S	-0.75	15
Cpd 150: 11.449 Cpd 151: Gibberellin A8	11.449 11.449	858.3046 364.1524	Gibberellin A8	C19 H24 O7	C19 H24 O7	C19 H24 O7	-0.55	15
Cpd 152: Thr Trp Met	11.449	V	Thr Trp Met	C20 H28 N4 O5 S	C20 H28 N4 O5 S	C20 H28 N4 O5 S	14.35	7
Cpd 153: p- HYDROXYCINNAMALDEHYDE	11.45	148.0519	p- HYDROXYCINNAMALDEHYDE	C9 H8 O2	C9 H8 O2	C9 H8 O2	3.41	11
Cpd 154: 16-hydroxy-5- hexadecenoic acid	11.593		16-hydroxy-5-hexadecenoic acid	C16 H30 O3	C16 H30 O3	C16 H30 O3	2,48	15
Cpd 155: 10Z,12E- hexadecadienoic acid	11.595		10Z,12E-hexadecadienoic acid	C16 H28 O2	C16 H28 O2	C16 H28 O2	2.37	15
Cpd 156: 2-oxo- heptadecanoic acid Cpd 157: Gibberellin A8-	11.595	***************************************	2-oxo-heptadecanoic acid Gibberellin A8-catabolite	C17 H32 O3 C19 H22 O7	C17 H32 O3 C19 H22 O7	C17 H32 O3 C19 H22 O7	3.44 -2.77	15
catabolite	11.004	302.13/6	Cubberenin Pro Catabolite	C13 1122 U/	015 HZZ U/	112 HZZ U/	~2.77	15

Cpd 158: Idebenone Metabolite (Benzenedecaroic acid, 2-hydroxy-3,4- dimethoxy-6-methyl-5- (sulfooxy)-)	11.665	434.1559	Idebenone Metabolite (Benzenedecanoic acid, 2- hydroxy-3,4-dimethoxy-6- methyl-5-(sulfooxy)-)	C19 H30 O9 S	C19 H30 O9 S	C19 H30 C9 S	11.76	2
Cpd 159: p- HYDROXYCINNAMALDEHYDE	11.68	148.0519	p- HYDROXYCINNAMALDEHYDE	C9 H8 O2	C9 H8 O2	C9 H8 O2	3.46	11
Cpd 160: 7-[2- TRIFLUOROMETHYL-4-(2- HYDROXYPHENYL)-1,3- DIOXAN-cis-5-YL]-HEPT-5Z- FNOIC ACID	11.683	374.1351	7-[2-TRIFLUOROMETHYL-4- (2-HYDROXYPHENYL)-1,3- DIOXAN-cis-5-YL]-HEPT-5Z- ENOIC ACID	C18 H21 F3 O5	C18 H21 F3 O5	C18 H21 F3 O5	-2.65	15
Cpd 161: 11.801	11.801	495.151	i i					
Cpd 162: Metaproterenol	12.137	211.1204	Metaproterenol	C11 H17 N O3	C11 H17 N O3	C11 H17 N O3	2.29	10
Cpd 163: Mitoxantrone	12.137	444.2031	Mitoxantrone	C22 H28 N4 O6	C22 H28 N4 O6	C22 H28 N4 O6	4.98	2
Cpd 164: Atorvastatin	12.454	558.2445	Atorvas ta tin	C33 H35 F N2 O5	C33 H35 F N2 O5	C33 H35 F N2 O5	15.28	2
Cpd 165: Mefenamic acid	12.54	1= NO.4 (CHOCK)	Mefenamic acid	C15 H15 N O2	C15 H15 N O2	C15 H15 N O2	2.64	11
Cpd 166: Phenylbutazone glucuronide	12.553	Non-transpace	Phenylbutazone glucuronide	C25 H28 N2 O8	C25 H28 N2 O8	C25 H28 N2 O8	22.56	2
Cpd 167: FLUTRIMAZOLE	12.866	100000000000000000000000000000000000000	FLUTRIMAZOLE	C22 H16 F2 N2	C22 H16 F2 N2	C22 H16 F2 N2	-6.32	15
Cpd 168: 13.051	13.051	522.1507		WASSERSON AND THE RESERVE OF THE RES				
Cpd 169: Bilirubin	13.223		Bilirubin	C33 H36 N4 O6	C33 H36 N4 O6	C33 H36 N4 O6	5.88	3
Cpd 170: 4-Methoxycinnamic acid	13.389		4-Methoxycinnamic acid	C10 H10 O3	C10 H10 O3	C10 H10 O3	2.91	9
Cpd 171: 13.403	13.403	508.1712			-			
Cpd 172: 4-Methoxycinnamic acid	13.559	178.0625	4-Methoxycinnamic acid	C10 H10 O3	C10 H10 O3	C10 H10 O3	2.74	9
Cpd 173: Nalbuphine-6- sulfate	13.758	437.1487	Nalbuphine-6-sulfate	C21 H27 N O7 S	C21 H27 N O7 S	C21 H27 N O7 S	4.76	2
Cpd 174: 1alpha,25- dihydroxy-26,26,26,27,27,27- hexafluoro-16,17,23,23,24,24 hexadehydro-19-norvitamin D3 / 1a	13.895	506.2188	1alpha,25-dihydroxy- 26,26,26,27,27,27-hexafluoro 16,17,23,23,24,24- hexadehydro-19-norvitamin D3 / 1a	C26 H32 F6 O3	C26 H32 F6 O3	C26 H32 F6 O3	13.37	3
Cpd 175: beta-Erythroidine Cpd 176: 13.992	13.895 13.992	273.1358 553.323	beta-Erythroidine	C16 H19 N O3	C16 H19 N O3	C16 H19 N O3	2.35	15
Cpd 176: 13.992 Cpd 177: Zopiclone N-oxide	14.204		Zopiclone N-oxide	C17 H17 CI N6 O4	C17 H17 CI N6 O4	C17 H17 CI N6 O4	21.57	- 1
Cpd 178: 14.477	14.477	495.0673	Espicione il unioc	027 1127 01110 01	027 1127 01110 01			
Cpd 179: Ketotifen-N- glucuronide	14.483	486.1535	Ketotifen-N-glucuronide	C25 H28 N O7 S	C25 H28 N O7 S	C25 H28 N O7 S	10.56	5
Cpd 180: Anandamide (18:3, n-6)	14.681	321.2654	Anandamide (18:3, n-6)	C20 H35 N O2	C20 H35 N O2	C20 H35 N O2	4.39	2
Cpd 181: 14.701	14.701	555.3381					1	
Cpd 182: Pro Pro Phe	14.881	359.1842	Pro Pro Phe	C19 H25 N3 O4	C19 H25 N3 O4	C19 H25 N3 O4	0.87	15
Cpd 183: (6R)-vitamin D3 6,19-(4-phenyl-1,2,4- triazoline-3,5-dione) adduct / (6R)-cholecalciferol 6,19-(4- phe	15.146	559.3696	(6R)-vitamin D3 6,19-(4- phenyl-1,2,4-triazoline-3,5- dione) adduct / (6R)- cholecalciferol 6,19-(4-phe	C35 H49 N3 O3	C35 H49 N3 O3	C35 H49 N3 O3	13.85	2
Cpd 184: GPEtn(18:0/18:1(11Z))	15.331	717.5236	GPEtn(18:0/18:1(11Z))	C39 H76 N O8 P	C39 H76 N O8 P	C39 H76 N O8 P	10.16	13
Cpd 185: Lactone of PGF- MUM	15.334	296.1612	Lactone of PGF-MUM	C16 H24 O5	C16 H24 O5	C16 H24 O5	3.99	3
Cpd 186: 15.402	15.402	677.4688					***	
Cpd 187: 15.474	15.474	633.4425					*	
Cpd 188: GPCho(13:0/10:0[U])	15.55	608.4347	GPCho(13:0/10:0[U])	C31 H63 N O8 P	C31 H63 N O8 P	C31 H63 N O8 P	-9.2	13
Cpd 189: GPCho(O- 18:0/3:1(2E))	15.625	564.4087	GPCho(O-18:0/3:1(2E))	C29 H59 N O7 P	C29 H59 N O7 P	C29 H59 N O7 P	-10.29	2
Cpd 190: 15.701	15.701	501.3643	and the second		200302000			
Cpd 191: N- Acetylsphingosine	15.786	341.2915	N-Acetylsphingosine	C20 H39 N O3	C20 H39 N O3	C20 H39 N O3	4.37	2
Cpd 192: Phytosphingosine	16.557	317.2916	Phytosphingosine	C18 H39 N O3	C18 H39 N O3	C18 H39 N O3	4.37	7
Cpd 193: 10,16-dihydroxy- palmitic acid	17.573	288.2312	10,16-dihydroxy-palmitic acid	C16 H32 O4	C16 H32 O4	C16 H32 O4	-3.86	15
Cpd 194: 27-nor-5b- cholestane-3a, 7a, 12a, 24, 25- pentol	18.106	438.3321	27-nor-5b-cholestane- 3a,7a,12a,24,25-pentol	C26 H46 O5	C26 H46 O5	C26 H46 O5	5.58	1
Cpd 195: 27-nor-5b- cholestane-3a, 7a, 12a, 24, 25- pentol	18.275	438.3321	27-nor-5b-cholestane- 3a,7a,12a,24,25-pentol	C26 H46 O5	C26 H46 O5	C26 H46 O5	5.51	1
Cpd 196: 18.675	18.675	478.0644					50 20	
Cpd 197: 18.686	18.686	636.2949						
Cpd 198: Epigallocatechin gallate	19.283	2	Epigallocatechin gallate	C22 H18 O11	C22 H18 O11	C22 H18 O11	7.58	3
Cpd 199: 19.283	19.283	478.0644						
Cpd 200: S-(p- Azidophenacyl)glutathione	19.795	466.1204	S-(p- Azidophenacyl)gluta thione	C18 H22 N6 O7 S	C18 H22 N6 O7 S	C18 H22 N6 O7 S	14.3	2

Compound Label	Name	m/z	RT	Algorithm	Mass
Cpd 1: isoamyl nitrite	isoamyl nitrite	118.0857	0.505	Find by Molecular Feature	117.0783